Advertisement

Topics

PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER

12:18 EDT 23 Aug 2017 | Medscape

"These drugs have achieved the dubious distinction of being the most expensive preventive therapies by far in the history of cardiovascular medicine," says an editorial.
Medscape Medical News

Original Article: PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER

NEXT ARTICLE

More From BioPortfolio on "PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...